Sarepta療法 SRPT 深 滬
已收盤 05-08 16:00:00 美东时间
19.955
-0.845
-4.06%
華盛通- 最 高20.84
- 今 開20.75
- 成交量 407.75万股
- 最 低 19.87
- 昨 收 20.80
- 總市值 21.07亿
- 52周最高 44.14
- 市盈率 靜 --
- 換手率 3.86%
- 52周最低 10.415
- 委 比 64.05%
- 總股本 1.06亿
- 歷史最高 181.83
- 量 比 1.19
- 振 幅 4.66%
- 歷史最低 0.433
- 每 手 1
- 風險率 6.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Sarepta Therapeutics shares are trading lower. The company reported Q1 financial results.
Sarepta Therapeutics shares are trading lower. The company reported Q1 financia...
05-07 04:56
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
04-17 00:59
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod
Roche (RHHBY) announced on Thursday that it is initiating a new Phase 3 trial for Elevidys, a treatment it developed with Sarepta Therapeutics (SRPT) for the muscle-wasting disorder. Duchenne muscular...
04-16 22:53
罗氏获欧洲监管机构反馈后，启动Elevidys基因疗法新研究
罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症（DMD），由罗氏...
04-16 20:44
Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus
U.S. stocks ended Friday broadly lower, with selling pressure intensifying across sectors as investors weighed persistent geopolitical risks tied to tensions in the Middle East. The tech-focused Nasda...
03-29 21:05
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.
03-28 01:09
美股大行评级 | 大摩、高盛上调Denali Therapeutics目标价；Chewy、沛齐遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Atossa Therapeutics"买入"评级，目标价从7美元升至25美元；Needham：维持Nkarta"买入"评级，目标价从10美元升至11美元
03-27 10:22
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13
Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
03-26 23:25
